期刊
INTERNATIONAL JOURNAL OF CANCER
卷 115, 期 4, 页码 519-527出版社
WILEY
DOI: 10.1002/ijc.20867
关键词
HER2; HER3; trastuzumab; breast cancer; antibody therapy
类别
Two members of the EGF receptor family, HER2 and HER3, act as key oncogenes in breast cancer cells. A MAb against HER2, trastuzumab, interferes with HER2 signaling and istherapeutically effective in humans. Here, we explored the biologic effects of an antibody against HER3 (alpha-HER3(ECD)) in the invasive breast cancer cell lines MCF-7 ADR and MDA-MB-468. Pretreating the breast cancer cells with alpha-HER3(ECD) prior to Heregulin stimulation caused significant reduction or the migratory and proliferative properties. This reduction is due to a substantial decrease in the tyrosine phosphorylation content of HER2 and to a modification of the HER2/HER3 association, which ultimately inhibits the activity of the downstream effectors phosphatidyinositol-3-OH-kinase and c-jun-terminal kinase. Furthermore, HER3 is internalized and riot activated by HRG after pretreatment with ECD alpha-HER3(ECD). Our data reinforce the notion that HER3 could be a key target in cancer drug design and show the great potential of anti-HER3 antibodies for the therapy of breast cancer and other malignancies characterized by overexpression of HER3. (c) 2005 Wiley-Liss, Inc.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据